TMCnet News
Houlihan Lokey Expands Healthcare Group with New Hire to Head Its Biopharma PracticeHoulihan Lokey (NYSE:HLI), the international investment bank, today announced that Fedora Baloiu has joined the firm as Head of the Biopharmaceutical practice in the firm's Healthcare Group. Ms. Baloiu will be focusing on advising pharma, biotech and biopharma services and technology clients globally. She is based in New York, reporting to Mark Francis, Managing Director and Head of the Healthcare Group. Ms. Baloiu joins from Goldman Sachs, where she has spent the last nine years in the Healthcare group within the Investment Banking Division in New York, focusing on pharmaceutical and biotech clients. While at Goldman, Ms. Baloiu worked on multiple M&A and financing transactions in the biopharma space and spent 18 months in the London office. Prior to Goldman Sachs, she worked in Bain & Company's Consumer and Healthcare Group, providing strategic management consulting services to clients throughout Europe. Over the course of her career, Ms. Baloiu has advised on M&A and financing transactions with an aggregate value in excess of $65 billion. "We are delighted that Fedora is joining our healthcare team and we look forward to collaborating with her to create significant success for clients in the biopharmaceutical sector," said Mr. Francis. "Her client relationships and depth of expertise in biopharmaceutical sector is tremendously valuable in both U.S. and Europe, where we see a sustaied high level of M&A activity," he added. "Houlihan Lokey's Healthcare Group has had tremendous success in providing world class advice to clients and assisting them in achieving market-leading outcomes. The Healthcare team has deep relationships with strategics, financial sponsors, and financing sources and provides a broad range of services and superior advice resulting in compelling solutions for clients," said Ms. Baloiu. "I am excited to join a market-leading Healthcare team and I look forward to working with my colleagues to continue the momentum the Group has achieved to date. I expect the Biopharma and related services to continue the tremendous growth experienced in recent years and I am eager to build upon such opportunities with a leading team," she continued. Houlihan Lokey has approximately 1,000 employees across 20 global locations and is a long-term leader in the mid-cap M&A market. With over 30 dedicated banking professionals, Houlihan Lokey's Healthcare Group is among the largest in financial services. Following Ms. Baloiu's hire, the Group's coverage capabilities span every vertical across the healthcare sector. In 2014, the Group ranked #1 for US transactions under $1 billion, according to Thomson Reuters (News - Alert). Ms. Baloiu holds a B.A. in Finance from Bocconi University and an MBA from Columbia Business School. About Houlihan Lokey Houlihan Lokey is an international investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments worldwide with offices in the United States, Europe, and the Asia-Pacific region. Independent advice and intellectual rigor are hallmarks of our commitment to client success across our advisory services. Houlihan Lokey is ranked as the No. 1 M&A advisor for U.S. transactions under $5 billion, the No. 1 global restructuring advisor, and the No. 1 M&A fairness opinion advisor for U.S. transactions over the past 10 years, according to Thomson Reuters (News - Alert). For more information, please visit www.hl.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151005005355/en/ |
